Home > Cardiology > ACC 2024 > Best of Posters > SGLT2 inhibition in heart failure more advantageous for women than men

SGLT2 inhibition in heart failure more advantageous for women than men

Presented by
Dr Mounica Vorla, University of Louisville School of Medicine, USA
ACC 2024
A meta-analysis compared the benefit of heart failure therapy with SGLT2 inhibitors versus placebo in women and men showing a risk reduction for women.

Currently, SGLT2 inhibitors form part of the guideline-recommended standard-of-care in the treatment of heart failure with various ejection fractions, as they have demonstrated benefits in cardiac and renal protection, independent of HbA1c, blood pressure, weight, and kidney function [1,2]. In heart failure trials, women are mostly underrepresented leading to a lack of sex-specific cardiovascular (CV) outcome data [1,3]. To gain further insight into this matter, Dr Mounica Vorla (University of Louisville School of Medicine, KY, USA) and colleagues performed a meta-analysis of randomised, placebo-controlled trials that provided results stratified by sex [1]. Pooled risk ratios (RR) for the primary composite outcomes were determined using a random effects model that included data from 11 studies.

For women, this comparison of SGLT inhibition with placebo led to a pooled RR of 0.76 (95% CI 0.69–0.82; P<0.00001). For men, the pooled RR was 0.80 (95% CI 0.73–0.87; P<0.00001). Furthermore, the results of the meta-analysis observed reductions in all-cause and CV death, along with hospitalisation for heart failure. Of note, the study authors conceded some limitations to their analysis, including the lack of patient-level data and heterogeneity between the included trials.

    1. Vorla M, et al. SGLT2 inhibitors in women and cardiovascular outcomes - meta-analysis of sex differences in eleven randomised controlled clinical trials. Session 1039-11, ACC 2024 Scientific Session, 6–8 April, Atlanta, USA.
    2. Rosano G, et al. Card Fail Rev. 2020:6:e31.
    3. Bozkurt B, Khalaf S. Methodist Debakey Cardiovasc J. 2017;13(4):216-223.

Copyright ©2024 Medicom Medical Publishers

Posted on